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OBJECTIVE: This study aimed to evaluate long-term weight loss in overweight hypertensive patients receiving
dietary counseling.
METHODS: Longitudinal study included overweight hypertensive patients who had an initial individual consultation
with a nutritionist between January 2002 and December 2005 and were followed for four years in a hypertension
clinic. Patients who had at least four consultations during the follow-up period were included in the dietary
counseling group. Those who scheduled their first consultation but missed that appointment or had fewer than four
consultations during the follow-up period were allocated to the control group. Target Energy intake was calculated
at 20–25 kcal/kg actual body weight/day.
RESULTS: The study included 102 patients aged 55¡1 years old (58 in the dietary counseling group). As compared
with the control group, patients in the dietary counseling group showed a significantly greater reduction in body
weight (-3.6¡0.8 vs. 0.8¡0.7 kg), which remained significant after controlling for age, gender, baseline body mass
index, and the use of different antihypertensive and antidiabetic drugs. Weight loss between 5.0% and 9.9% was
observed in a significantly higher percentage of patients in the dietary counseling group (28% vs. 11%). A weight
loss of at least 10% was only observed in dietary counseling group patients, who had a significantly lower odds ratio
for increasing the number and/or dosage of antihypertensive agents, even after controlling for age, gender, and
baseline body mass index.
CONCLUSIONS: Dietary counseling may be associated with long-term weight loss in overweight hypertensive
patients.
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INTRODUCTION
Obesity is an increasingly prevalent condition throughout
the world.1 Body mass index (BMI) is directly associated
with high blood pressure and the prevalence of hyperten-
sion.2-5 Even a modest adult weight gain substantially
increases the risk for hypertension while weight loss
reduces blood pressure.6 Overweight and obese hyperten-
sive patients are advised to lose weight to ideally reach a
BMI lower than 25 kg/m2.2,7-8 However, decreases in blood
pressure occur before and/or without reaching this desired
body weight. Weight losses as little as 5.1 kg can decrease
systolic and diastolic blood pressures by 4.4 mmHg and
3.6 mmHg, respectively.9
Dietary intervention is an important aspect in the
treatment of excess body weight.10 A clinically significant
weight loss can be obtained with relatively short-term (i.e.,
sixmonths to one year) dietary interventions based on energy
restriction, regardless of the macronutrient emphasized.11-13
However, obesity is a chronic disease, and weight regain is a
disappointingly common problem. Consequently, a long-
term approach to treatment is needed.10-15 The effect of
dietary counseling on long-term weight change is not clear.
The literature on the long-term follow-up of dietary
treatment for patients with obesity indicates an overall
median success rate of 15%.16 In a recent meta-analysis of
randomized controlled trials, nutritional interventions pro-
duced a mean 6% weight loss after one year. Approximately
half of the initial weight loss was regained after three years.13
Despite evidence that hypertensive patients with excess
body weight should lose weight and that lifestyle modifica-
tions are essential to treat obesity, specific data on the effect
of dietary counseling on the long-term weight loss of
hypertensive individuals are scarce. Therefore, this study
aimed to evaluate long-term weight loss in overweight
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hypertensive patients receiving dietary counseling. A
secondary purpose was to investigate whether dietary
counseling is related to modifications in the metabolic
profile, blood pressure levels, and the use of antihyperten-
sive, antidiabetic, and lipid-lowering drugs.
METHODS AND MATERIALS
This was a longitudinal study carried out with over-
weight and obese hypertensive outpatients from the
Hypertension Clinic (CLINEX) of the Rio de Janeiro State
University. The Hypertension Clinic is a Brazilian referral
center for the multidisciplinary care of hypertensive
patients, who are referred by their physicians for individual
dietary counseling with nutritionists. Regular dietary
counseling, however, depends on the patient’s willpower.
Patients can schedule dietary counseling at any time during
their treatment at the Hypertension Clinic.
The inclusion criteria were as follows: hypertensive
patients who had their first individual consultation with a
nutritionist between January 2002 and December 2005 and
were followed for four years at the Hypertension Clinic;
between 30 and 80 years old in age; and BMI of at least
25 kg/m2 (adult) or 27 kg/m2 (elderly).
The exclusion criteria were as follows: current use of
medications for weight loss; high level of physical activity;
and recent (i.e., within the previous six months) changes in
dietary intake, body weight ($3 kg), or the intensity or
frequency of physical exercise. In addition, patients with
any of the following were also excluded from the study:
eating disorders, major depression, a medical history of
drug addiction, hypothyroidism, insulin-dependent dia-
betes, diseases severely affecting the gastrointestinal and
renal systems, and a coronary event or stroke in the three
months preceding the selection. Pregnant or lactating
women were also excluded.
One hundred forty-eight individuals aged 36 to 78 years
old, without gender distinction, were enrolled. Dietary
counseling was offered every month during the first three
months of treatment and every three months thereafter. The
nutritionist provided face-to-face counseling that was
individually tailored to each patient. Each counseling
session lasted 30 to 60 minutes, during which nutritionists
strongly recommended that patients follow an energy-
restricted diet and increase their physical activity level,
primarily through light- to moderate-intensity leisure
activities such as walking. The goal of weight loss was to
achieve and maintain a 5% to 10% body weight reduction.
All participants consumed self-selected foods. Neither
vitamins nor other nutritional supplements were prescribed.
Energy intake was calculated to provide 20 to 25 kcal/kg
of actual body weight/day with&15% to 20% of calories
from protein, 25% to 30% from fat, and 50% to 60% from
carbohydrate. Patients were advised to limit their consump-
tion of energy-dense snacks. Sodium intake was restricted to
2400 mg/day. All patients were also instructed about the
dietary approaches to stop hypertension (DASH) eating
plan, which aims to increase the consumption of fruits,
vegetables, and low-fat dairy products and to reduce
saturated and total fat intake. Specific dietary counseling
was provided to patients with type 2 diabetes and/or
dyslipidemia according to the recommendations of the
American Diabetes Association17 and the National
Cholesterol Education Program.18 Strategies for continued
success were developed and reinforced at each visit.
Patients were considered hypertensive if their systolic and/
or diastolic blood pressure levels were at least 140 and
90 mmHg, respectively, or if they were on antihypertensive
therapy.7 Diabetes mellitus was diagnosed when fasting
glucose was at least 126 mg/dL on two different days or when
patients were using insulin or an oral antidiabetic medication
for at least eight weeks.19 The diagnosis of dyslipidemia
followed the Adult Treatment Panel III criteria18 (total
cholesterol $200 mg/dL, low-density lipoprotein cholesterol
$130 mg/dL, or triacylglycerols $150 mg/dL) or was deter-
mined by the use of lipid-lowering drugs.
Blood samples were collected after a 12-hour fasting
period. All biochemical analysis was performed at the
clinical laboratory of the Pedro Ernesto University Hospital.
Biochemical evaluation examined glucose, total cholesterol,
high-density lipoprotein cholesterol, low-density lipopro-
tein cholesterol, and triacylglycerols. Fasting plasma glucose
was determined by the glucose oxidase method. The serum
lipid profile, including total cholesterol, triacylglycerols,
and high-density lipoprotein cholesterol, was assessed
using an automated analyzer. If triacylglycerol was lower
than 400 mg/dL, low-density lipoprotein cholesterol was
calculated using the Friedewald formula.20 Uric acid was
measured with an automated technique. Serum urea
nitrogen and plasma creatinine were assessed using a
kinetic method.
Blood pressure was determined with the auscultatory
method in the non-dominant arm after a resting period of at
least 10 minutes in the sitting position. A standard mercury
sphygmomanometer was used with an appropriate cuff size
for each patient. The first value was discarded, and the
mean of at least three readings was analyzed.
Height and weight were measured according to standar-
dized procedures; the former was measured with a
stadiometer that was accurate within ¡0.5 cm while the
latter was measured with a calibrated scale that was
accurate within ¡0.1 kg (Filizola S.A., Sa˜o Paulo, SP,
Brazil) when patients wore light clothing and no shoes.
BMI was calculated with the standard formula (kilograms/
meters squared).
The study protocol was approved by the committee on
ethics of the Pedro Ernesto University Hospital.
Statistical analysis
Continuous variables were expressed as means ¡
standard errors. To test the possible relation of dietary
counseling with changes in body weight, biochemical
variables and drugs used, patients were stratified into two
groups according to adhesion to the dietary counseling
provided by nutritionists. Patients who had at least four
consultations during the four-year follow-up period of the
study were included in the dietary counseling group (DCG).
Hypertensive patients who scheduled their first consulta-
tion with the dietitian but missed that appointment or had
fewer than four consultations during the following four
years were allocated to the control group (CG). Continuous
variables were compared between the two groups using the
Student’s t test, and multiple linear regression analysis was
used to adjust for factors that could interfere with weight
loss (i.e., age, gender, baseline BMI, and the use of
antihypertensive and antidiabetic drugs). To evaluate
differences in body weight changes between the groups
Long-term weight loss hypertensives
Torres MRSG et al.
CLINICS 2011;66(10):1779-1785
1780
during the study at months 0, 6, 12, 24, 36, and 48, repeated
measures ANOVA was applied. The chi-square test was
used for comparisons between groups of gender distribui-
tion, prevalence of diabetes and dyslipidemia, and use of
drugs. Associations between dietary counseling and
changes in the use of different drugs were assessed through
multiple logistic regression analysis. As we aimed to
evaluate the association between dietary counseling per se
and changes in the use of drugs in an observational study,
we adjusted our results for factors that could interfere with
drug use, specifically gender, age, baseline BMI, and weight
loss during the study period. Considering the means and
standard deviations of weight loss in both groups during
the study period and given a desired power of 0.8, we found
that the minimum sample size necessary in each group was
22 participants. We also tested our study power in light of
the means and standard deviations of weight loss in both
groups during the study period, which was 1.00. Stata 10
(Stata Corp., College Station, TX, USA) was used for
statistical analysis. A p-value ,0.05 was considered statis-
tically significant.
RESULTS
Of the 148 patients who scheduled their first consultation
with the dietitian between January 2002 and December 2005
and were eligible for the study, 46 did not complete four
years of follow-up in the Hypertension Clinic and were
excluded from the study. Therefore, 102 patients (44 men and
58 women) were included in the final analyses. The patients’
mean age was 55.1¡0.9 years, and their mean BMI was
32.2¡0.5 kg/m2. On average, participants included in the
study had three to four consultations/year with physicians,
and two to three consultations/year with nutritionists. After
stratifying the patients according to their dietary counseling
(i.e., DCG and CG), both groups were comparable in terms of
several demographic, clinical, and biochemical characteris-
tics at the beginning of follow-up (Table 1).
Patients in the DCG showed a significantly greater
reduction in body weight during the study period as those
in the CG (Figure 1). The difference in weight loss between
the two groups remained significant after controlling for
age, gender, baseline BMI, and the use of antihypertensive
and antidiabetic drugs that could interfere with body
weight (p,0.001).
In the DCG, most weight loss occurred in the first six
months. At six months, the change from the baseline body
weight was significant: -2.80¡0.47 kg (-3.2%), p,0.0001. At
twelve months of follow-up, this group continued losing
weight, and the change compared with baseline was -
3.50¡0.69 kg (-4.0%). At 24 months of follow-up, patients
were still losing weight: -3.83¡0.80 kg (-4.3%). After 24
months, patients in the DCG started to regain weight.
However, body weight compared with the baseline remained
significant lower (p,0.0001) at 36 months [-3.61¡0.76 kg (-
4.1%)] and 48 months [-3.64¡0.79 kg (-3.9%)].
Figure 2 shows that at the end of follow-up, a significantly
lower percentage of patients in the DCG gained weight as
compared with those in the CG. In both groups, only 2% of
patients maintained their weight while 32% lost between
0.1% and 4.9% of their initial body weight. A weight loss of
5.0% - 9.9% (as compared with baseline body weight) was
observed in a significantly higher percentage of DCG
patients. Weight losses of at least 10% were seen only in
DCG patients.
The metabolic variables and blood pressure values during
follow-up were compared between groups, and no sig-
nificant change was observed in the CG. However, in the
DCG, significant reductions in glucose, total cholesterol, and
triglycerides were observed (Table 2).
Patients in the DCG had a significantly lower odds ratio for
increasing the number and/or dosage of antihypertensive
agents, even after controlling for age, gender and baseline
BMI. However, after adjusting for weight loss, the odds ratio
was no longer significantly lower in the DCG (Table 3).
Table 1 - Baseline characteristics of participants according to dietary counseling.
Characteristics Dietary counseling group (n = 58) Control group (n = 44) p
Age (years) 54.93¡1.20 55.35¡1.47 0.82
Gender (women/men) 28 (48%) /30 (52%) 30 (68%) /14 (32%) 0.05
Body weight (kg) 86.82¡1.93 83.12¡1.98 0.19
Body mass index (kg/m2) 32.42¡0.63 31.87¡0.71 0.57
Glucose (mg/dL) 120.73¡5.53 119.07¡6.15 0.84
Urea (mg/dL) 34.03 ¡ 1.79 33.46¡2.24 0.11
Creatinine (mg/dL) 0.92¡0.05 0.91¡0.07 0.64
Uric acid (mg/dL) 6.00¡0.36 5.70¡0.44 0.60
Total cholesterol (mg/dL) 219.04¡6.51 230.26 ¡ 8.72 0.37
HDL cholesterol (mg/dL) 45.88¡1.88 46.48¡2.30 0.84
LDL cholesterol (mg/dL) 137.84¡8.01 149.08¡10.43 0.39
Triglycerides (mg/dL) 190.07¡19.58 183.85 ¡ 20.62 0.83
Systolic blood pressure (mmHg) 140.94¡2.33 141.75¡2.93 0.83
Diastolic blood pressure (mmHg) 88.05¡1.40 87.95¡1.65 0.96
Mean blood pressure (mmHg) 105.68¡1.53 105.89¡1.92 0.93
Heart rate (bpm) 72.68¡1.51 71.92¡1.75 0.74
Type 2 diabetes (n; %) 16 (28%) 14 (32%) 0.64
Dyslipidemia (n; %) 47 (81%) 35 (80%) 0.57
Use of antidiabetic drugs (n; %) 10 (17%) 10 (23%) 0.55
Use of lipid-lowering drugs (n; %) 12 (21%) 9 (20%) 0.91
Number of antihypertensive agents 2.25¡0.13 2.25¡0.13 1.00
Values are expressed as mean ¡ standard error or percentage.
HDL=high-density lipoprotein, LDL= low-density lipoprotein.
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The DCG also had a lower odds ratio for beginning the
use or increasing the number and/or dosage of antidiabetic
drugs after controlling for age, gender, and baseline BMI
(Table 3).
DISCUSSION
In the present study, using a sample of hypertensive
patients with excess body weight, followed up for four years
and stratified into two groups according to dietary
counseling, the main finding was the significantly greater
weight loss observed in the DCG. Moreover, a significantly
lower percentage of individuals who increased the number
of antihypertensive agents and/or their dosage during
follow-up was observed in the DCG as compared with
those in the CG.
At sixmonths of follow-up, patients in the DCG had lost an
average of 2.8 kg, which is lower than the results seen in other
trials employing comprehensive lifestyle interventions in
hypertensive or prehypertensive individuals.21-23 In the
intensive intervention phase (Phase I) of the Weight-Loss
Maintenance Trial,21 after six months of intervention, over-
weight and obese adults on medications for hypertension
and/or dyslipidemia showed a mean weight loss of 5.8 kg.
Cakir and Pinar (2006)22 conducted a six-month randomized
controlled trial on comprehensive lifestyle modification in
hypertensive patients. The intervention group showed a
mean weight loss of 3.8 kg. This difference in weight loss at
six months of follow-up between other studies and ours may
be explained by the fact that in other studies, a higher number
of weight-loss counseling sessions were offered. For example,
in the intensive intervention phase (Phase I) of the Weight-
Loss Maintenance Trial,21 20 group weight-loss counseling
sessions were offered over six months while in our study,
three individual weight-loss counseling sessions were
offered during the first six months.
At 12 and 24 months of follow-up, the mean weight loss in
the DCG was 3.5 kg and 3.8 kg, respectively, similar to the
results of other studies.24-25 In a multicenter randomized
trial24 involving 810 adults with prehypertension or stage 1
hypertension, patients were assigned to one of the following
three groups: an advice-only comparison group (i.e.,
‘‘advice only’’); an intervention group following an estab-
lished guideline-recommended lifestyle (i.e., ‘‘established’’);
or an intervention group following the established guide-
line-recommended lifestyle in addition to the DASH eating
plan (i.e., ‘‘established plus DASH’’). As compared with
the ‘‘advice only’’ group, both behavioral interventions
Figure 1 - Mean change in body weight during the study period according to dietary counseling. (M=month).
Figure 2 - Stratification of participants according to percentage change in body weight in both study groups.
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significantly reduced body weight after 18 months of
follow-up. Weight loss was 3.8 kg in the ‘‘established’’
group and 4.3 kg in the ‘‘established plus DASH’’ group.24
In the Nonpharmacologic Interventions in the Elderly
(TONE) Trial, the average reduction in weight for the
participants assigned to weight loss intervention was
approximately 3.8, 3.6, and 3.9 kg at the 9-, 18- and 30-
month follow-up visits, respectively.25
Little is known about the efficacy of long-term lifestyle
interventions for weight loss in hypertensive individuals. In the
Treatment of Mild Hypertension Study (TOMHS), the weight
loss with lifestyle intervention was 4.5 kg (5.6%) at one year,
3.6 kg (4.5%) at two years, 3.2 kg (4.0%) at three years, and
2.3 kg (3.0%) at four years.26 The weight loss obtained in that
study at four years of follow-up is lower than that observed in
DCG patients in our study for the same period (3.6 kg; 3.9%).
In our study, the weight loss in the DCG during the first six
months was lower than that observed in other studies21-23 and,
at one year, lower than that reported in the TOMHS Study.26
However, at the end of the follow-up (four years), the weight
loss in our study was greater than that observed in the TOMHS
Study.26 This is an important finding because, as mentioned in
the introduction, the greatest difficulty to treat obesity is to
maintain weight loss. The greater weight loss at four years of
follow-up in the present study’s DCG may have many
explanations. One explanation may be the lower weight loss
of our patients in the beginning of the follow-up, because a
moderateweight loss, as comparedwith amore substantial one,
Table 2 - Metabolic variables and blood pressure levels at baseline (Month 0) and at the end of follow-up (Month 48) in
the two groups.
Dietary counseling group
(n = 58)
Control group
(n = 44) p**
Month 0 Month 48 D p* Month 0 Month 48 D p*
Glucose (mg/dL) 120.73¡5.53 108.48¡4.15 -12.25¡4.15 0.009 119.07¡6.15 117.67¡7.28 -1.40¡7.30 0.85 0.18
Urea (mg/dL) 34.03¡1.79 35.16¡2.16 1.13¡1.71 0.51 33.46¡2.24 36.80¡2.24 3.36¡1.94 0.10 0.41
Creatinine (mg/dL) 0.92¡0.05 0.98¡0.05 0.06¡0.03 0.05 0.91¡0.07 0.94¡0.05 0.04¡0.05 0.46 0.68
Uric acid (mg/dL) 6.00¡0.36 5.63¡0.35 -0.36¡0.25 0.17 5.70¡0.41 5.73¡0.41 0.03¡0.31 0.92 0.33
Total cholesterol (mg/
dL)
219.04¡6.51 202.31¡5.60 -16.73¡5.40 0.003 230.26¡8.72 221.00¡8.49 -9.26¡8.34 0.28 0.43
HDL-cholesterol (mg/
dL)
45.88¡1.88 43.71¡1.56 -2.17¡1.36 0.12 46.48¡2.30 46.13¡2.28 -0.34¡1.92 0.86 0.43
LDL-cholesterol (mg/
dL)
137.84¡8.01 133.50¡7.10 -4.33¡8.60 0.62 149.08¡10.43 147.79¡8.74 -1.29¡10.13 0.90 0.83
Triglycerides (mg/dL) 190.07¡19.58 163.15¡13.61 -26.92¡12.7 0.04 183.85¡20.62 157.85¡17.11 -26.00¡19.1 0.18 0.97
Systolic BP (mmHg) 140.95¡2.33 138.58¡2.69 -2.36¡2.85 0.41 141.75¡2.93 143.02¡2.72 1.27¡3.57 0.72 0.42
Diastolic BP (mmHg) 88.05¡1.40 85.23¡1.71 -2.81¡1.67 0.10 87.95¡1.65 88.41¡1.81 0.45¡2.09 0.83 0.22
Mean BP (mmHg) 105.68¡1.53 103.02¡1.86 -2.67¡1.92 0.17 105.89¡1.92 106.61¡1.96 0.73¡2.44 0.77 0.27
Heart rate (bpm) 72.68¡1.51 71.45¡1.59 -1,24¡1.92 0.52 71.92¡1.75 72.10¡1.48 0.18¡2.19 0.93 0.63
Data are expressed as mean ¡ SEM.
HDL=high-density lipoprotein, LDL= low-density lipoprotein, BP=blood pressure, D=Month 48 – Month 0.
*Month 0 vs. Month 48.
**Dietary counseling group vs. control group.
Table 3 - Odds ratios (95% CIs) for the changes in the use of antihypertensive, antidiabetic, and lipid-lowering drugs
during the study period according to dietary counseling.
Control group (n = 44) Dietary counseling group (n = 58) p
Increased the number and/or dosage of antihypertensive agents
N of cases (%) 28 (64%) 21 (36%) -
Odds ratio (95% CI) 1.00 0.32 (0.14 - 0.74) 0.008
Multivariate-adjusted* 1.00 0.38 (0.16 - 0.90) 0.03
Multivariate-adjusted** 1.00 0.36 (0.15 - 0.87) 0.02
Multivariate-adjusted*** 1.00 0.48 (0.19 – 1.22) 0.12
Began to use or increased the number and/or dosage of
antidiabetic drugs
N of cases (%) 11 (25%) 7 (12%) -
Odds ratio (95% CI) 1.00 0.41 (0.14 – 1.17) 0.09
Multivariate-adjusted* 1.00 0.31 (0.10 - 0.97) 0.04
Multivariate-adjusted** 1.00 0.30 (0.09 - 0.95) 0.04
Multivariate-adjusted*** 1.00 0.36 (0.11 – 1.22) 0.10
Began to use or increased the dosage of lipid-lowering drugs
N of cases (%) 7 (16%) 4 (7%) -
Odds ratio (95% CI) 1.00 0.40 (0.11 - 1.47) 0.17
Multivariate-adjusted* 1.00 0.36 (0.09 - 1.36) 0.13
Multivariate-adjusted** 1.00 0.36 (0.09 - 1.39) 0.14
Multivariate-adjusted*** 1.00 0.34 (0.08 - 1.47) 0.15
* = adjusted for gender and age.
** = adjusted for gender, age, and body mass index at baseline.
*** = adjusted for gender, age, body mass index at baseline, and weight loss during the study period.
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is more likely to be maintained over a longer period of time.27
Nevertheless, the weight loss observed during the first year in
the TOMHS Study is in accordance with the recommendations
for lifestyle interventions of different guidelines.8,10
In the present study, a significantly lower percentage of
individuals in the DCG as compared with CG patients
increased the number and/or dosage of antihypertensive
and antidiabetic agents (after adjusting for age and gender)
during follow-up. These findings can be explained by the
greater weight loss observed in the DCG; after adjusting for
that variable, the difference between groups was no longer
significant. More than 40% of patients in the DCG lost $5%
of their initial body weight while only 11% of patients in the
CG reached that level of weight loss. A modest weight loss
(,5% to 10% of the initial weight) contributes to important
health benefits, improving many of the obesity-related risk
factors for cardiovascular disease, such as insulin resistance,
dyslipidemia, hypertension, and inflammation.8,10,28-29 In
patients on antihypertensive medication, a modest weight
loss improves blood pressure control, reducing or even
eliminating the need for antihypertensive medication.25,30-33
The blood pressure–lowering effect of weight loss is most
likely a result of an improvement in insulin sensitivity and a
decrease in the sympathetic nervous system activity, and it
occurs independently of salt restriction.27
A recent review of 18 trials with a wide variation in
follow-up durations (i.e., two weeks to three years) has
found that weight-reducing diets for overweight hyperten-
sive individuals can induce a modest 3% to 9% weight loss
and may decrease the dosage requirements of those on
antihypertensive medications.32
Although weight loss can be the most important reason
for the lower percentage of patients in the DCG who
increased the number and/or dosage of antihypertensive
agents, DCG patients were also instructed to modify their
ingestion of different dietary components that affect blood
pressure, such as sodium, potassium, calcium, magnesium,
and alcohol, and they were encouraged to follow the DASH
eating plan.2,7,34 Gusma˜o et al. observed that a special care
program, including multidisciplinary activities, increases
blood pressure control.35
In addition, only the DCG patients had a significant decrease
in glucose, total cholesterol, and triglycerides during the study,
which can be explained by their greater weight loss and the
specific dietary counseling for the treatment of hyperglycemia
and dyslipidemia that they received.
Our study has several limitations, the greatest being that it
was not a randomized trial. Patients were allocated in both
groups according to their willpower. Most likely, patients in
the DCG were more interested in losing weight than those in
the CG. However, in randomized trials, only individuals
willing to undergo the intervention are included in the study.
Although our intervention was not as intensive as those of
other trials, we aimed to evaluate weight loss in patients
receiving a feasible dietary treatment currently offered to our
patients, rather than amore intensive intervention that would
not be continued after the end of the study. Another
important limitation is that this was a single-center study.
CONCLUSIONS
In conclusion, our study suggests that dietary counseling
could be associated with long-term weight loss in over-
weight hypertensive patients.
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